covid
Buscar en
Allergologia et Immunopathologia
Toda la web
Inicio Allergologia et Immunopathologia Hypocomplementemia in the absence of autoantibodies in women with recurrent preg...
Información de la revista
Vol. 35. Núm. 3.
Páginas 90-94 (mayo 2007)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 35. Núm. 3.
Páginas 90-94 (mayo 2007)
Acceso a texto completo
Hypocomplementemia in the absence of autoantibodies in women with recurrent pregnancy loss
Hipocomplementemia en ausencia de autoanticuerpos en mujeres con abortos repetidos
Visitas
6481
D. Michelouda, E. Sarmientoa, R. Teijeiroa, J. Jensena, JJ. Rodríguez Molinaa, E. Fernández-Cruza, J. Carbonea
a Department of Immunology. University Hospital Gregorio Marañon. Madrid. Spain.
Este artículo ha recibido
Información del artículo
Resumen
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Tablas (2)
Table 1. Clinical characteristics and immunological abnormalities in a cohort of 201 women with recurrent PL and 30 parous healthy women
Table 2. Clinical characteristics of women with recurrent PL associated with hypocomplementemia in the absence of autoantibodies
Mostrar másMostrar menos
Background. Accumulating data suggest an immunopathogenic role for the complement system as a causative element in pregnancy loss (PL). Formation of pathogenic antibodies with activation of the classical pathway may have a role, but this mechanism fails to characterize the majority of cases with recurrent PL. We established the prevalence of hypocomplementemia without circulating autoantibodies in women with recurrent PL. Methods: In a retrospective case control study, 201 women with recurrent PL (two or more PL) and 30 healthy women who had normal pregnancies but no PL were studied. Serum levels of C3, C4, and factor B were determined by nephelometry. Total hemolytic activity of the complement system (CH100) was investigated by radial immunodiffusion test. Results: The prevalence of hypocomplementemia [low levels of C3, C4, FB or CH100 (with normal concentrations of C3, C4 and FB)] was significantly higher in women with recurrent PL (22,4 %) in comparison with controls (6.6 %; p = 0.019). C3, C4, FB hypocomplementemia or low CH100 were observed in 13 (6,5 %), 19 (9,4 %), 13 (6.5 %) and 7 (3,5 %) women with recurrent PL, respectively. Among patients with C3, C4, FB or CH100 hypocomplementemia, 10, 18, 12 and 5 patients had no circulating autoantibodies [antinuclear antibodies, anticardiolipin antibodies or antithyroid antibodies], respectively. In all, hypocomplementemia, in the absence of autoantibodies, was observed in 38 (18,9 %) women with recurrent PL in a significantly higher frequency than controls (n = 2, p = 0.049). Conclusions: Hypocomplementemia, in the absence of autoantibodies was observed in a group of women with recurrent PL which might suggest a role of the complement system in the pathogenesis of PL in these patients.
Keywords:
Pregnancy loss
Abortion
Complement
Hypocomplementemia
Autoantibodies
Antecedentes. Un cúmulo de datos sugiere que el sistema complemento juega un papel destacado como elemento inmunopatogénico en la interrupción espontánea del embarazo. La formación de anticuerpos patógenos que activen la vía clásica del complemento puede jugar un papel, pero este mecanismo falla al caracterizar la mayoría de los casos de aborto recurrente. Nosotros establecemos la prevalencia de la hipocomplementemia sin anticuerpos circulantes en mujeres con abortos recurrentes. Métodos. En un estudio retrospectivo se estudiaron 201 mujeres con aborto recurrente (2 o más abortos) y 30 mujeres sanas que habían tenido embarazos normales, pero no abortos. Por nefelometría se valoraron los niveles de C3, C4 y factor B. La actividad del sistema complemento (CH100) se estudio por inmunodifusión radial. Resultados. La prevalencia de hypocomplementemia (niveles bajos de C3, C4, FB o CH100 ¿con concentraciones normales de C3, C4 y FB) fue significativamente más elevada en mujeres con aborto recurrente (22,4%) en comparación con los controles (6,6%; p=0.019). C3, C4, hypocomplementemia FB o CH100 bajo, se observaron respectivamente en 13 (6,6%), 19 (9,4%), 13 (6,5%) y 7 (3,5%) de mujeres con abortos repetidos. Entre las pacientes con C3, C4, FB o CH100 hipocomplementemia, 10, 18, 12 y 5, respectivamente no tenían autoanticuerpos circulantes (anticuerpos antinucleares, anticardiolipina o antitiroides). En todas, hipocomplementemia en ausencia de autoanticuerpos, se observó en 38 (18,9%) mujeres con aborto recurrente y con una significativa mayor frecuencia que en los controles (n=2, p=0.049). Conclusiones. Hipocomplementemia en ausencia de autoanticuerpos se observó en un grupo de mujeres con aborto recurrente, lo que podría sugerir el papel del sistema complemento en la patogénesis de los abortos de estas pacientes.
Texto completo

INTRODUCTION

Factors involved in pregnancy loss (PL) due to abnormal fetomaternal tolerance are poorly understood. PL has been shown to be associated in a proportion of cases with the antiphospholipid syndrome (APS) or with aberrant natural killer cell activity which indicate that the etiology may involve some form of immune dysfunction1.

A novel role for complement as an effector in the pathway leading to PL has been suggested2. However, the clinical significance of complement is unclear in patients with unexplained PL. Low levels of complement 3 (C3) and/or complement 4 (C4) are reported to be associated with the APS3. In the mouse model, activation of maternal C3 through the alternative pathway has been shown enough to mediate defects in placenta formation and subsequent PL which is independent of the presence of B cells and autoantibodies2.

Identification of complement activation as a mediator of PL and definition of the complement components necessary to trigger such injury is likely to lead to a better understanding of its pathogenesis and to new and improved treatments.

In the present study we determined the prevalence of hypocomplementemia in a cohort of women with recurrent PL, with special attention given to women without circulating autoantibodies.

MATERIALS AND METHODS

In a retrospective transversal study we investigated 201 women with recurrent PL in the Immunology Department at the University Hospital Gregorio Marañón. The patients were admitted to the hospital or followed at the outpatient clinic for other Departments (Genetics, Infertility or Obstetrics), with a history of recurrent spontaneous PL. Recurrent PL was defined by the loss of two or more consecutive pregnancies of non-viable foetuses1.

In order to exclude other causes of recurrent PL, paternal chromosomes, uterine anomalies and endocrine pathologies had been evaluated before by the referral departments.

To investigate possible causes of hypocomplementemia, histories of the patients were carefully reviewed by the same immunologist for any clinical criteria of autoimmune diseases, hepatopathy and concomitant chronic infections known to be associated with complement consumption. Clinical manifestations of APS were considered according to recent Sydney consensus document4. An underlying autoimmune disease was considered when the patients met specific criteria according to the American College of Rheumatology criteria5-6. If the patient's AST and/or ALT level rose above 1.25 fold above the upper level of normal even once, they were classified as having hepatopathy. In all cases the serum was recovered from the blood samples by sedimentation at 1500 Xg and was thawed and analyzed by nephelometry (Beckman-Coulter). Total haemolytic activity of the complement system (CH100) was investigated by radial immunodiffusion test. In this study, low levels of complement factors C3, C4, Factor B (FB) and CH100 were define as lower than the 5th percentile obtained in 30 age-matched healthy women who had normal pregnancies but no PL (healthy controls): < 72, < 14, < 21 mg/dl and < 26 CH100 Units/ml, respectively. As pregnancy may have an effect on complement levels we included women who were parous as controls7. Control women were drawn from a normal population after completion of a questionnaire. Immunological studies of patients and controls were performed at least three months after PL or successful pregnancy, respectively.

Other immunological parameters that were collected included IgG and IgM anticardiolipin antibodies (ACA, measured by ELISA), IgG and IgM anti-β2-glycoprotein-I antibodies (anti-β2-GP-I, measured by ELISA), antinuclear antibodies (ANA, measured by indirect immunofluorescence), anti-DNA antibodies (anti-DNA, measured by ELISA), anti-thyroid antibodies (measured by ELISA) and immunoglobulin (Ig) G, IgA and IgM levels (measured by nephelometry, Beckman-Coulter). Lupus anticoagulant was performed by coagulimetric tests in the Haematology Department. In this study we defined high title ANA when the title was ≥ 1/160. Hypergammaglobulinemia was defined as the presence of serum concentrations of immunoglobulins > 95th percentile observed in healthy controls (IgG > 1403 mg/dl, IgA > 415 mg/dl, IgM > 211 mg/dl).

RESULTS

Clinical and immunological characteristics of the 201 women with recurrent PL and of 30 parous healthy women are shown in table 1.

The prevalence of hypocomplementemia [low levels of C3, C4, FB or CH100 (with normal concentrations of C3, C4 and FB)] was significantly higher in women with recurrent PL (45 out of 201 patients, 22,4 %) in comparison with controls (2 out of 30 women, 6.6 %; 2-sided Fisher's exact test, p = 0.019).

C3 hypocomplementemia was observed in 13 (6.5 %) women with recurrent PL. The mean concentration of C3 in this group was 61 mg/dl (range: 22-71 mg/dl). At these group of women with low C3 complement, 10 patients had no circulating autoantibodies [high titer ANA (> 1/160), moderate-high titer IgG or IgM ACA (> 20 Units/ml) or antithyroid antibodies) and 3 had autoantibodies [IgG-ACA (n = 2) and IgM-ACA (n = 1)]. Low C3 was observed in 1 healthy woman.

C4 hypocomplementemia was detected in 19 patients (9.45 %, mean concentration of C4: 12 mg/dl, range: 8-13 mg/dl). 18 patients had no positive autoantibodies and one patient showed a positive lupus anticoagulant. Low C4 levels in combination with low CH100 activity was observed in one healthy control.

Factor B hypocomplementemia occurred in 13 patients (6,5 %, mean concentration of FB: 17 mg/dl, range: 12-20 mg/dl). Only one patient had positive autoantibodies (IgG-ACA).

Low CH100 with normal nephelometric values of C3, C4 and Factor B was observed in 7 patients (3,5 %, medium level of CH100: 22 Units/ml, range: 18-23 Units/ml). Five of these patients did not have circulating autoantibodies. One woman had low CH100 values in association with positive IgG-ACA and one patient had positive lupus anticoagulant.

Overall, 38 (18.9 %) patients with recurrent PL had data of hypocomplementemia in the absence of autoantibodies in perypheral blood in a significantly higher frequency than parous healthy women (n = 2, p = 0.049). Clinical characteristics of patients with hypocomplementemia in the absence of autoantibodies are shown in table 2.

When we compared the levels of complement factors of women with recurrent PL without autoantibodies to women with recurrent PL and positive autoantibodies, there were not significant differences. When the data for complement levels were analyzed by gestational age at pregnancy loss there were not significant differences between women with early PL (< 10 weeks) and late PL (> 10 weeks).

DISCUSSION

Even though pregnancy presents an immunological riddle in that the mother does not reject semi-allogenic fetus, few alterations of this critical balance appear to occur during normal pregnancy, as most pregnancies proceed to term without major complications. Disturbances in this delicate balance may, however, play an important role in serious pregnancy-related disorders, most prominently in cases with recurrent PL1.

A fully active complement system deriving from the maternal circulation as well as from local production by various cell sources is present in the placenta8. The role of this system at the placental level, as in any other tissue in the body, is to protect both the fetus and the mother against infectious and other toxic agents. As fetal tissues are semi-allogenic and alloantibodies commonly develop in the mother, the placenta is potentially subject to complement-mediated immune attack at the feto-maternal interface with the potential risk of PL. Experimental observations suggest that inappropriate complement activation during pregnancy impairs this type of immunoregulation8-11.

A role for complement as effector of PL has been suggested in different clinical settings. Within APS associated PL, involvement of the complement system has been demonstrated. Experiments performed in a mouse model of APS showed that activation of the complement cascade is required to induce PL and thrombosis12-13. Interestingly enough, heparin, the standard anticoagulant treatment used to prevent obstetric complications in patients with APS14 has been shown to have "anti-complementary effects"15-19. Even in the absence of detectable anticoagulation, heparin prevented antiphospholipid antibody-induced PL and inhibited systemic complement activation20.

Although formation of pathogenic antibodies with activation of the classical pathway may have a role, this mechanism fails to characterize the majority of cases with unexplained recurrent PL. It is, however, possible that complement activation is also involved in other causes of recurrent PL. Indeed, in antibody-independent mouse models, it has been recently demonstrated that complement activation is a required event in the pathogenesis of placental and fetal injury2,21. A few studies have associated early and late PL with the onset of hypocomplementemia and, in some conditions, with complement deposition in the placenta22-23.

With the limitations of a retrospective study using chart review, we detected a group of women with recurrent PL and significant hypocomplementemia, including low C3, low C4, low FB or low CH100 (with normal values of C3, C4 and FB), without presence of autoantibodies or other secondary conditions that could explain low concentrations of complement factors. Low CH100 with normal values of C3, C4 and FB might be indicative of deficiency of other complement factors such as C5 (not tested in our study). Asymptomatic partial primary complement deficiencies should be taken into account as a possible explanation for the low levels of complement factors observed in some of these patients. However, that a subgroup of women with unexplained recurrent PL had hypocomplementemia, in the absence of known causes of complement consumption, might also suggest activation of maternal complement factors.

Whether hypocomplementemia is the cause or effect of PL in these women can't be explained by this study. In this regard, further prospective studies in a larger number of patients are encouraged to establish whether the complement system might be implicated in mechanisms of recurrent PL in women with unexplained recurrent PL independently of the presence of detectable serum autoantibodies.

ACKNOWLEDGEMENTS

The authors acknowledge Margarita Rodriguez-Mahou for the performance of autoantibody detection tests at the Autoimmunity Section. JC was supported by Fundacion Salud 2000 (Ayudas Serono 2005), Madrid, Spain.


Correspondence:
Dr. J. Carbone
Department of Immunology
University Hospital Gregorio Marañon
Dr Esquerdo 46
28007 Madrid. Spain
Phone: +34 91 4265180
FAX: +34 91 5866698
E-mail: carbone@teleline.es

Bibliography
[1]
Carrington B, Sacks G, Regan L..
Recurrent miscarriage:pathophysiology and outcome. Curr Opin Obstet Gyneco, 17 (2005), pp. 591-7
[2]
Mao D, Wu X, Deppong C, Friend LD, Dolecki G, Nelson DM et al..
-dependent mechanisms through complement alternative pathway. Immunit, 19 (2003), pp. 813-22
[3]
Sasaki S, Murase T, Kuno S, Yamamoto T..
Changes of complement in recurrent abortion and pregnancy loss with antiphospholipid antibody positive. Nihon Rinsho Meneki Gakkai Kaish, 29 (2006), pp. 372-7
[4]
Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R et al..
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemos, 4 (2006), pp. 295-306
[5]
Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF et al..
revised criteria for the classification of systematic lupus. Arthritis Rheu, 25 (1982), pp. 1271-7
[6]
Hunder GG, Arend WP, Bloch DA, Calabrese LH, Fauci AS, Fries JF et al..
criteria for the classification of the vasculitis. Arthritis Rheu, 33 (1990), pp. 1065-7
[7]
Richani K, Soto E, Romero R, Espinoza J, Chaiworapongsa T, Nien JK et al..
Normal pregnancy is characterized by systemic activation of the complement system. Matern Fetal Neonatal Me, 17 (2005), pp. 239-45
[8]
Holmes CH, Simpson KL..
Complement and pregnancy: new insights into the immunobiology of the fetomaternal relationship. Baillieres Clin. Obstet..
Gynaecol, 6 (1992), pp. 439
[9]
Rooney IA, Oglesby TJ, Atkinson JP..
Complement in human reproduction: activation and control..
Immunol. Re, 12 (1993), pp. 276-94
[10]
Holers VM, Girardi G, Mo L, Guthridge JM, Molina H, Pierangeli SS et al..
Complement C3 activation is required for the antiphospholipid antibody-induced fetal loss. J. Exp..
Med, 195 (2002), pp. 211-20
[11]
Xu C, Mao D, Holers MV, Palanca B, Cheng AM, Molina H..
A critical role for murine complement regulator Crry in fetomaternal tolerance. Scienc, 287 (2000), pp. 498-501
[12]
Girardi G, Salmon JB..
The role of complement in pregnancy and fetal loss. Autoimmunit, 36 (2003), pp. 19-26
[13]
Pierangeli SS, Girardi G, Vega-Osterlag M, Liu X, Espinola RG, Salmon J..
for antiphospholipid antibody-mediated thrombofilia. Arthritis Rheu, 52 (2005), pp. 2120-4
[14]
Derksen RH, Khamashta MA, Branch DW..
Management of the obstetric antiphospholipid syndrome. Arthritis Rheu, 50 (2004), pp. 1028-39
[15]
Loos M, Bitter-Suermann D..
Mode of interaction of different polyanions with the first (C1,C1) the second (C2) and the fourth (C4) component of complement. IV..
in serum by polyanions. Immunolog, 31 (1976), pp. 931-4
[16]
Fiedel BA, Rent R, Myhrman R, Gewurz H..
Complement activation by interaction of polyanions and polycations. Immunolog, 30 (1976), pp. 161-9
[17]
Weiler JM, Yurt RW, Fearon DT, Austen KF..
b, Bb, by native and commercial heparin. J Exp Me, 147 (1978), pp. 409-21
[18]
Kazatchkine MD, Fearon DT, Metcalfe DD, Rosenberg RD, Austen KF..
convertase. J Clin Inves, 67 (1981), pp. 223-8
[19]
Edens RE, Linhardt RJ, Bell CS, Weiler JM..
Heparin and derivatized heparin inhibit zymosan and cobra venom factor activation of complement in serum. Immunopharmacolog, 27 (1994), pp. 145-53
[20]
Girardi G..
Heparin treatment in pregnancy loss:Potential therapeutic benefits beyond anticoagulation. J Reprod Immuno, 66 (2005), pp. 45-51
[21]
Girardi G, Yarilin D, Thurman JM, Holers VM, Salmon JE..
Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Me, 203 (2006), pp. 2165-75
[22]
Cunningham DS, Tichenor JR..
Decay-accelerating factor protects human trophoblast from complement-mediated attack. Clin..
Immunol. Immunopatho, 74 (1995), pp. 156
[23]
Richani K, Romero R, Soto E, Espinoza J, Nien JK, Chaiworapongsa T et al..
Unexplained intrauterine fetal death is accompanied by activation of complement. Perinat Me, 33 (2005), pp. 296-305
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos